1. Home
  2. BLZE vs PHAT Comparison

BLZE vs PHAT Comparison

Compare BLZE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Backblaze Inc.

BLZE

Backblaze Inc.

HOLD

Current Price

$13.23

Market Cap

762.0M

Sector

Technology

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$7.57

Market Cap

676.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLZE
PHAT
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
762.0M
676.3M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
BLZE
PHAT
Price
$13.23
$7.57
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$7.60
$19.83
AVG Volume (30 Days)
2.1M
1.1M
Earning Date
05-04-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
58.56
42.72
EPS
N/A
N/A
Revenue
$145,835,000.00
$175,110,000.00
Revenue This Year
$10.16
$93.04
Revenue Next Year
$10.91
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
14.27
216.93
52 Week Low
$3.26
$7.59
52 Week High
$23.99
$18.31

Technical Indicators

Market Signals
Indicator
BLZE
PHAT
Relative Strength Index (RSI) 42.46 32.70
Support Level $12.15 N/A
Resistance Level $14.19 $9.74
Average True Range (ATR) 0.69 0.50
MACD -0.03 -0.12
Stochastic Oscillator 40.55 1.56

Price Performance

Historical Comparison
BLZE
PHAT

About BLZE Backblaze Inc.

Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: